IPO Trending
WINDLASEQ / NSE, BSEListed

Windlas Biotech Limited

Incorporated in 2001, Windlas Biotech Ltd is a prominent pharmaceutical company in India’s CDMO segment, offering end-to-end services from product discovery and development to licensing and commercial manufacturing of generic and complex generic products. The company also markets its own branded products in the trade generics and OTC segments, focusing on chronic therapeutic categories related to lifestyle disorders. Windlas Biotech operates across three verticals: CDMO services, domestic trade generics and nutraceuticals, and exports. Its marquee clients include Pfizer, Sanofi India, Cadila Healthcare, Emcure Pharmaceuticals, Eris Lifesciences, Intas Pharmaceuticals, and Systopic Laboratories. The company’s Dehradun-based manufacturing facilities have an installed capacity of 7,063.83 million tablets/capsules, 54.46 million pouches/sachets, and 61.08 million liquid bottles.

₹448 - ₹460Open
Listed Price437.00
Listing Gain-5.00%
TimelineBookbuilding IPO
Open04 Aug 2021
Close06 Aug 2021
Allotment11 Aug 2021
Listing16 Aug 2021

Quota Reservation Portions

QIBPortion: 43,64,510 shares
50%
Nii (hni)Portion: 13,09,354 shares
15%
RetailPortion: 30,55,159 shares
35%

Minimum Application Bracket Matrix

Retail1 lots / 30 shares
₹13,800
sHNI15 lots / 450 shares
₹2,07,000
bHNI73 lots / 2,190 shares
₹10,07,400

About the Company

Incorporated in 2001, Windlas Biotech Ltd is a prominent pharmaceutical company in India’s CDMO segment, offering end-to-end services from product discovery and development to licensing and commercial manufacturing of generic and complex generic products. The company also markets its own branded products in the trade generics and OTC segments, focusing on chronic therapeutic categories related to lifestyle disorders. Windlas Biotech operates across three verticals: CDMO services, domestic trade generics and nutraceuticals, and exports. Its marquee clients include Pfizer, Sanofi India, Cadila Healthcare, Emcure Pharmaceuticals, Eris Lifesciences, Intas Pharmaceuticals, and Systopic Laboratories. The company’s Dehradun-based manufacturing facilities have an installed capacity of 7,063.83 million tablets/capsules, 54.46 million pouches/sachets, and 61.08 million liquid bottles.

Company Promoters

Ashok Kumar WindlassHitesh WindlassManoj Kumar WindlassAKW WBL Family Pvt Trust
Windlas Biotech Limited IPO Details | GMP, Allotment & Financials | IPO Trending